Efficacy of TAK-085 in Participants With Hypertriglyceridemia

PHASE3CompletedINTERVENTIONAL
Enrollment

611

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hypertriglyceridemia
Interventions
DRUG

Omega-3-acid ethyl esters 90 (TAK-085)

Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

DRUG

Eicosapentaenoic acid-ethyl (EPA-E)

EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY